Related references
Note: Only part of the references are listed.Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma
Agata Malenda et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions
Charlotte Lees et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
Ziju Y. Xu-Monette et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Genetic alterations and their clinical implications in DLBCL
Yi Miao et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma
Anja Mottok et al.
BLOOD (2019)
Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Jeremy S. Abramson
CANCER (2019)
Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma
Esther Hian Li Chan et al.
CANCER MEDICINE (2019)
Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma
Alex F. Herrera et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
Pier Luigi Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma
Yucai Wang et al.
BLOOD CANCER JOURNAL (2019)
Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade
Bjoern Chapuy et al.
BLOOD (2019)
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope
Georg Hopfinger et al.
HEMASPHERE (2019)
The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma
Sarah Tomassetti et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
The unique biology and treatment of primary mediastinal B-cell lymphoma
Alessandro Broccoli et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant
Santosha Vardhana et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma
Yosuke Tanaka et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes
Poonam K. Panjwani et al.
HUMAN PATHOLOGY (2018)
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma
Xiaoxiao Wang et al.
NEOPLASIA (2018)
Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens
Anja Mottok et al.
BLOOD (2018)
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis
Nirav N. Shah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma
Y. Xia et al.
LEUKEMIA (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies
Kieron Dunleavy
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R
Lisa Giulino-Roth et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma
Jinfen Wang et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma
Pier Luigi Zinzani et al.
BLOOD (2017)
Primary mediastinal large B-cell lymphoma
Maurizio Martelli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial
Pier Luigi Zinzani et al.
BLOOD (2017)
The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome
Jacob R. Bledsoe et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma
Matthew W. Jackson et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients
Katharina Troppan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma
T. Aoki et al.
BLOOD CANCER JOURNAL (2015)
Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression
Anja Mottok et al.
CELL REPORTS (2015)
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group
Noelia Purroy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma
Abraham Avigdor et al.
ANNALS OF HEMATOLOGY (2014)
Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
David D. W. Twa et al.
BLOOD (2014)
[18F] Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study
Maurizio Martelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease
Jacob D. Soumerai et al.
LEUKEMIA & LYMPHOMA (2014)
Regulation of B-cell development and function by microRNAs
Virginia G. de Yebenes et al.
IMMUNOLOGICAL REVIEWS (2013)
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
Kieron Dunleavy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
C. Visco et al.
LEUKEMIA (2012)
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care
Theodoros P. Vassilakopoulos et al.
ONCOLOGIST (2012)
Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study
M. Rieger et al.
ANNALS OF ONCOLOGY (2011)
The molecular pathogenesis of primary mediastinal large B-cell lymphoma
Christian Steidl et al.
BLOOD (2011)
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
Christian Steidl et al.
NATURE (2011)
Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma
John Kuruvilla et al.
LEUKEMIA & LYMPHOMA (2008)
MicroRNAs: regulators of gene expression and cell differentiation
Ramesh A. Shivdasani
BLOOD (2006)
Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience
KJ Savage et al.
ANNALS OF ONCOLOGY (2006)
NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes
F Feuerhake et al.
BLOOD (2005)
Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated-with CHOP or MACOP-B/VACOP-B
G Todeschini et al.
BRITISH JOURNAL OF CANCER (2004)
Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma
C Guiter et al.
BLOOD (2004)
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
A Rosenwald et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
KJ Savage et al.
BLOOD (2003)
Share Paper
